Melanoma incidence in PD patients carrying LRRK2 gene mutations who had a heterozygous p.Gly2019Ser pathogenic variant was similar or even higher than the risk of the development of melanoma among patients with idiopathic PD [16,17]. This evidence concerns the gene LRRK2 and melanoma.